I am pleased to advise that multiple deals with pharmaceutical customers relating to our Unifill ® platform and other game-changing technologies are now either complete or in the final stages of negotiation.
We have successfully completed negotiations with a global pharmaceutical company for a major long-term supply contract for the Unifill syringe as referred to during our last earnings call. I can advise that this contract is finalized with all terms having been agreed upon by both parties. The formal process of having the execution copy of the contract signed is now taking place, and we have been advised by the customer that it may require an additional few days or weeks to complete. While this process is taking slightly longer than both parties originally anticipated, it is understandable given the size of the Company and the number of steps involved.
I share the eagerness of many of our stockholders regarding this upcoming news, which I believe will accelerate our commercial progress. However I am also not concerned about one contract with one customer taking a little longer to announce than expected. Our focus is to build long term partnerships with a diversified customer base and deliver substantial revenue and sustainable growth over coming years. In that regard, I am very pleased with the fundamentals of our Company and excited about our future. I would therefore like to take this opportunity to update you on some other significant commercial developments.
We expect to finalize negotiations with several additional pharmaceutical companies relating to our Unifill platform of syringes this calendar year. I believe that some of these upcoming agreements have the potential to be of equal or even greater financial magnitude than the contract I referred to above. In parallel, we are also continuing to supply Unifill syringes to a number of other pharmaceutical companies who are conducting human factor studies, drug co